semaglutide for liver disease Receives FDA Approval Treatment of MASH Landmark Study Finds Semaglutide Effectively

For a closer look at this topic, see How Much Glutamine for Gut Health, which explores how glutamine fits into digestive wellness

Secondary endpoints included several cardiovascular and renal outcomes, such as: Expanded cardiovascular composite outcomes Progression of chronic kidney disease Outcomes related to peripheral artery disease and heart failure The trial was event-driven, continuing until 1,225 adjudicated primary endpoint events occurred

The frequency of gastrointestinal adverse effects decreases over time after the initial 8 weeks treatment period [44,49-51]

Terren C, Fransolet Mt, Ancion M, Nisolle M, Munaut C

Filgotinib improved health-related quality of life and led to comprehensive disease control in individuals with ulcerative colitis: data from the selection Trial

Int J Mol Sci 24(3):2737 Contella L et al (2024) Impact of Substance use disorder on tryptophan metabolism through the kynurenine pathway: a narrative review